Safety and Efficacy at 240 Weeks of Different Raltegravir Formulations in Children with HIV-1: a Phase 1/2 Open Label, Non-Randomised, Multicentre Trial.
The Lancet HIV（2018）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined